The Cooper Companies, Inc. 8K This presentation contains forward-looking | COO 14 Nov 07

NYSE: COO

Exhibit 99.1

11/13/2007

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking

projections of Cooper’s results. Actual results could

differ materially from these projections. Additional

information concerning factors that could cause

material differences can be found in Cooper’s periodic

filings with the Securities and Exchange Commission.

They are available publicly and on request from

Cooper’s investor relations department.

11/13/2007

THE COMPANY

Medical devices

Vision care

Women’s healthcare

Market leadership

Favorable demographics

Consistent long-term performance

11/13/2007

CONSISTENT PERFORMANCE

(CAGR Ex Call Outs)

17%

26%

30%

2001-

2006

5 Year CGR

EPS -

Continuing

Operations

Operating Income

Revenue

11/13/2007

COO BUSINESS

GOALS

Low to mid-teens revenue growth for

next five years

CVI double digit

CSI high-teens, including M&A

Earnings growth mid-teens to high-

teens

11/13/2007

COO BUSINESS

GOALS

CooperVision

Grow 1.5 times worldwide market

next 5 years

Largest specialty lens company

Move to #2 position worldwide

Operating margin mid to upper 20’s

11/13/2007

COO BUSINESS

GOALS

CooperSurgical

Revenue of $300M by 2011

including acquisitions

Operating margin in mid 20’s

11/13/2007

CooperVision

11/13/2007

11/13/2007

MARKET SEGMENTS

(worldwide, millions of $’s)

$2,555

$1,718

$2,082

$1,191

All Other Spheres

Specialty

$6,778

$4,732

Total Market

Daily Disposable

Spheres

11%

$2,505

$1,459

CGR

2011

2006

11/13/2007

GEOGRAPHIC MARKET SEGMENTS

$6,778

$4,732

Total Market

*Includes Mideast and Africa

Source: company reported data and independent market audit

Asia/Pacific

Europe*

Americas

(millions of $’s)

12%

$2,555

$1,440

$1,559

$1,328

$2,665

$1,964

CGR

2011

2006

11/13/2007

WORLD MARKET DRIVERS

Growing indication: myopia

Favorable demographics: teens

Specialty and value-added vs.

commodity: improved lens

technology

Geographic expansion

11/13/2007

COOPERVISION TODAY

$800M in 2007 vs. $38M in 1994

#2 in Europe; #2 in US; #3 worldwide

Specialty lenses

Worldwide toric lens market leader

11/13/2007

Contact Lens Global Market*

% change and %

*Independent audit data

100

Total

Specialty

-2

n/c

-2

n/c

Reusable

Sphere

+29

+12

+31

+10

Single Use

CVI

YTD07

CVI

Q307

11/13/2007

Contact Lens Global Market*

US versus ROW

*Independent audit data

100%

Total

22% (+1)

33% (n/c)

Specialty

33% (-3)

-2

57% (-2)

Reusable

Sphere

45% (+2)

+10

10% (+2)

Single Use

%ROW

YTD07

%US

YTD07

11/13/2007

Contact Lens Global Market*

% change

*Independent audit data

Total

+21

+10

+21

+10

Asia

n/c

Europe

United States

CVI

YTD07

CVI

Q307

11/13/2007

Contact Lens Global Market*

Q307 versus Q207

*Independent audit data

+n/c

Total

Asia

n/c

Europe

-2

United States

CVI

MKT

11/13/2007

Contact Lens Global Market*

Competitive Landscape

% change

*Independent audit data

Total (100%)

-5

-11

Others (40%)

COO (17%)

+15

+14

JNJ (43%)

YTD

11/13/2007

Revenue Guidance

($Millions)

*as issued on 9/6/07

$1,020 -

$1,090

$940 -

$967

TOTAL

$165 -

$170

$150 -

$157

CSI

$855 -

$920

$790 -

$810

CVI

2008

2007*

11/13/2007

UPDATES

•

Manufacturing capacity

•

New Products

–

2 week silicone hydrogel

–

Silicone hydrogel toric

–

Proclear

daily disposable in Japan

11/13/2007

Keeping you at the forefront of women’s healthcare™

WOMEN’S

HEALTHCARE

11/13/2007

WOMEN’S HEALTHCARE

Favorable demographics

Pharma, capital equipment, in-office

Fragmented market

Changing market dynamics

11/13/2007

Consolidate market

New in-office product opportunities

Fertility and hospital procedures

Disposable/reusable components

COOPERSURGICAL STRATEGY

11/13/2007

PROCEDURES

Cervical disease

Incontinence

Infertility

Osteoporosis (diagnostic)

Menstrual disorders

Menopause

Birth control

11/13/2007

COOPERSURGICAL TODAY

$125M FY 2006

Consumables 85%; capital

equipment 15%

In-office market segment leader

Recent acquisitions

U.S. 85%

11/13/2007

CSI OBJECTIVES

$125M 2006 –

$300M 2011

25% operating margin

Expand in hospital segment

20% ROI M&A hurdle

Accelerate organic growth

Expand geographically

11/13/2007

NYSE:COO

Financial Highlights

11/13/2007

Total Debt

$861

Stockholders’

Equity

$1435

Total Capitalization

$2297

Total Debt /Capitalization 38%

CAPITAL STRUCTURE 7-31-07

($’s in Millions)

11/13/2007

COO CONSOLIDATED REVENUE

$244

$330

$389

$698

$734

$71

$82

$101

$109

$125

$100

$200

$300

$400

$500

$600

$700

$800

$900

2002

2003

2004

2005

2006

($ in millions)

$315

$412

CVI

CSI

$490

$807

$859

11/13/2007

CONSOLIDATED OPERATING INCOME

$189

$95

$67

$117

$175

$50

$100

$150

$200

2002

2003

2004

2005

2006

10%

15%

20%

25%

($ in millions)

Operating Income

Operating Margin

(Ex Call Outs)

11/13/2007

CVI CONSOLIDATED OPERATING INCOME

$60

$89

$107

$171

$186

$50

$100

$150

$200

2002

2003

2004

2005

2006

10%

20%

30%

($ in millions)

Operating Income

Operating Margin

(Ex Call Outs)

11/13/2007

CSI CONSOLIDATED OPERATING INCOME

$20

$21

$18

$14

$24

$10

$15

$20

$25

2002

2003

2004

2005

2006

10%

15%

20%

25%

($ in millions)

Operating Income

Operating Margin

(Ex Call Outs)

11/13/2007

TAXES

Net Operating Loss

Carryforwards $143 million

Global Tax Arrangement

Effective Tax Rates

11/13/2007

CASH FLOW FROM OPERATING

ACTIVITIES

$56

$80

$101

$184

$151

$50

$100

$150

$200

2002

2003

2004

2005

2006

($ in millions)

11/13/2007

HISTORY OF SUCCESSFUL DELEVERAGING

38%

27%

20%

21%

34%

31%

23%

36%

35%

10%

20%

30%

40%

Jan.’05 –

Acquired

Ocular Sciences

Feb.’02 –

Acquired

Biocompatibles

Dec.’97 –

Acquired

Aspect Vision

Nov.’06 –

Acquired

Lone Star

Nov.’05 –

Acquired Inlet

& NeoSurg

DEBT/CAP

NYSE: COO

The Cooper Companies, Inc. (COO) 8-KThis presentation contains forward-looking